1 / 9

Glecaprevir-Pibrentasvir in Cirrhotic Genotypes: Expedition-1 Study

Explore the efficacy and safety of glecaprevir-pibrentasvir treatment in cirrhotic patients with genotype 1, 2, 4, 5, and 6 in the Expedition-1 study. The study highlights SVR12 results, drug dosing, baseline characteristics, adverse events, and conclusions.

coryr
Download Presentation

Glecaprevir-Pibrentasvir in Cirrhotic Genotypes: Expedition-1 Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1 Source: FornsX, et al. Lancet Infect Dis. 2017;17:1062-8.

  2. Glecaprevir-Pibrentasvirin Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Study Features Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  3. Glecaprevir-Pibrentasvirin Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Study Design 0 12 24 Week Genotypes1, 2, 4, 5, 6 Glecaprevir-Pibrentasvir(n = 146) SVR12 Drug DosingGlecaprevir-pibrentasvir (100/40 mg) fixed dose combination; three pills once daily Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  4. Glecaprevir-Pibrentasvirin Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Baseline Characteristics Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  5. Glecaprevir-Pibrentasvirin Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Baseline Characteristics Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  6. Glecaprevir-Pibrentasvirin Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Results 145/146 89/90 31/31 16/16 2/2 7/7 SVR12 by intent-to-treat analysis. One patient with GT1a experienced viral relapse at week 8 post-treatment and the patient had Y93N detected at baseline and at time of viral relapse. Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  7. Glecaprevir-Pibrentasvirin Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Adverse Events Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  8. Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6EXPEDITION-1: Conclusions Source: Forns X, et al. Lancet Infect Dis. 2017;17:1062-8.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related